-
公开(公告)号：US20170313777A1
公开(公告)日：2017-11-02
申请号：US15649791
申请日：2017-07-14
Inventor： Yao-Bin LIU , Patrick Mayes , Radha Shah Parmar
CPC classification number: C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO: 1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
-
公开(公告)号：US10351627B2
公开(公告)日：2019-07-16
申请号：US15246662
申请日：2016-08-25
Inventor： Yao-Bin Liu , Patrick Mayes , Radha Shah Parmar
IPC: C07K16/28 , A61K39/395 , A61K45/06 , C07K16/30 , A61K39/00
Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
-
公开(公告)号：US20160215059A1
公开(公告)日：2016-07-28
申请号：US15006560
申请日：2016-01-26
Inventor： Yao-Bin Liu , Patrick Mayes , Radha Shah Parmar
CPC classification number: C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to an ICOS binding protein, or antigen binding portion thereof that is an agonist human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more oft SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
Abstract translation: 本发明涉及ICOS结合蛋白或其抗原结合部分，其是激动剂人ICOS，并且当其与体内的T细胞接触时不诱导补体，ADCC或CDC，以及治疗癌症，感染性疾病和 /或与所述ICOS结合蛋白或其抗原结合部分的败血症。 此外，本发明的ICOS结合蛋白或其抗原结合部分当与所述T细胞接触时能够激活T细胞; 当与所述T细胞接触时刺激T细胞增殖和/或当与所述T细胞接触时诱导细胞因子产生。 本发明涉及包含SEQ ID NO：1中的一个或多个的ICOS结合蛋白或其抗原结合部分; SEQ ID NO：2; SEQ ID NO：3; SEQ ID NO：4; SEQ ID NO：5; 和/或SEQ ID NO：6。
-
公开(公告)号：US09914781B1
公开(公告)日：2018-03-13
申请号：US15351465
申请日：2016-11-15
Inventor： Tejinder Kaur Bhinder , Chong Ding , Xu Feng , Wenqing Jiang , Alan Peter Lewis , Yingli Ma , Guhan Nagappan , Radha Shah Parmar , Yangsheng Qiu , Liuqing Yang , Qing Zhang , Yanjiao Zhou
CPC classification number: C07K16/2863 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.
-
公开(公告)号：US09738718B2
公开(公告)日：2017-08-22
申请号：US15387161
申请日：2016-12-21
Inventor： Yao-Bin Liu , Patrick Mayes , Radha Shah Parmar
IPC: C07K16/28 , A61K39/395 , A61K39/00
CPC classification number: C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
-
Patent Agency Ranking
公开(公告)号：US20160362494A1
公开(公告)日：2016-12-15
申请号：US15246662
申请日：2016-08-25
Inventor： Yao-Bin LIU , Patrick Mayes , Radha Shah Parmar
CPC classification number: C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
Abstract translation: 本发明涉及ICOS结合蛋白或其抗原结合部分，该ICOS结合蛋白或其抗原结合部分是当与体内的T细胞接触时与人类ICOS的激动剂并且不诱导补体，ADCC或CDC，以及治疗癌症，感染性疾病和 /或与所述ICOS结合蛋白或其抗原结合部分的败血症。 此外，本发明的ICOS结合蛋白或其抗原结合部分当与所述T细胞接触时能够激活T细胞; 当与所述T细胞接触时刺激T细胞增殖和/或当与所述T细胞接触时诱导细胞因子产生。 本发明涉及包含以下一种或多种的ICOS结合蛋白或其抗原结合部分：SEQ ID NO：1; SEQ ID NO：2; SEQ ID NO：3; SEQ ID NO：4; SEQ ID NO：5; 和/或SEQ ID NO：6。
-
公开(公告)号：US20220064299A1
公开(公告)日：2022-03-03
申请号：US17412614
申请日：2021-08-26
Inventor： Yao-Bin LIU , Patrick Mayes , Radha Shah Parmar
IPC: C07K16/28 , A61K45/06 , C07K16/30 , A61K39/395
Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
-
公开(公告)号：US20180334503A1
公开(公告)日：2018-11-22
申请号：US15987996
申请日：2018-05-24
Inventor： Yao-Bin Liu , Patrick Mayes , Radha Shah Parmar
IPC: C07K16/28 , C07K16/30 , A61K39/395 , A61K45/06 , A61K39/00
CPC classification number: C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
-
公开(公告)号：US20180030136A1
公开(公告)日：2018-02-01
申请号：US15546369
申请日：2016-01-26
Applicant: GlaxoSmithKline Intellectual Property Development Limited , INSERM (Institut National de la Santé et de la Recherche Médicale) , INSTITUT JEAN PAOLI & IRENE CALMETTES , Université d'Aix-Marseille , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventor： Yao-Bin LIU , Patrick Mayes , Daniel OLIVE , Radha Shah Parmar
IPC: C07K16/28 , A61K39/395
CPC classification number: C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
-
公开(公告)号：US09771424B2
公开(公告)日：2017-09-26
申请号：US15006560
申请日：2016-01-26
Inventor： Yao-Bin Liu , Patrick Mayes , Radha Shah Parmar
IPC: A61K39/395 , C07K16/28 , A61K45/06 , C07K16/30 , A61K39/00
CPC classification number: C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to an ICOS binding protein, or antigen binding portion thereof that is an agonist human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.028 seconds)
